Papalocal
Loading…
News
← All news
Health

Cancer vaccines cut melanoma recurrence by 42%. A pioneer explains what comes next.

Dr. Catherine Wu of Dana-Farber helped invent personalized cancer vaccines a decade ago. Now Merck, Moderna, and the NIH are pouring money into the field — she explains why, and what the limits still are.

How does this story make you feel?

The announcement late last week by Merck and Cambridge-based Moderna — that patients given their melanoma vaccine after surgery faced a 42 percent lower risk of recurrence or death within two years compared with untreated patients — arrived in a field that has spent a decade quietly working toward exactly this kind of result. The National Institutes of Health said earlier this month that it plans to direct nearly $200 million toward an initiative designed to accelerate cancer vaccine therapies, the New York Times reported.

Few researchers have a longer view of that build-up than Dr. Catherine Wu of the Dana-Farber Cancer Institute. Nearly a decade ago, Wu published findings from a pioneering clinical trial that tested a personalized cancer vaccine in six melanoma patients, and subsequent follow-up studies showed the vaccine continued to shield those patients from recurrence years down the line. Now heading Dana-Farber's Division of Stem Cell Transplantation and Cellular Therapies, Wu sat down with the Boston Globe to discuss what the new findings and the NIH initiative mean for people with cancer.

Cancer vaccines are fundamentally different from the preventive shots most people know. Unlike traditional vaccines, which block infection before it takes hold, these treatments work by training T cells — white blood cells that are part of the immune system — to recognize the specific genetic markers on cancer cells and mount an immune response against them. Crucially, they also build what Wu calls immunologic memory.

Cancer vaccines seek to expand the army of T cells that can recognize cancer and go after the tumor, but what sets them apart is that they also have the ability to train T cells to remember. That's what we call immunologic memory. If there's another encounter in the distant future with a rogue cell, those T cells will say, 'Oh, I've seen you before. Zap, you're gone.'— Dr. Catherine Wu, Dana-Farber Cancer Institute

Tailored to the unique genetic makeup of an individual patient's tumor cells, most cancer vaccines rely on mRNA technology — the same platform used in COVID-19 vaccines. Wu was careful to note that the relationship between COVID vaccines and cancer vaccines runs in a less obvious direction than many assume.

Efforts to create mRNA cancer vaccines preceded the pandemic. It was a new kid on the block, borne out of a lot of the innovative work that was done by Nobel laureates [Katalin Karikó and Drew Weissman]. The rapid progress we made in COVID vaccines was borne on the foundation of what was already happening in cancer vaccines. The groups that made the vaccines operationalized the process. Now it's time to bring it back to cancer.— Dr. Catherine Wu, Dana-Farber Cancer Institute

Melanoma has been the proving ground for this work, and Wu explained why that is not a coincidence. The disease causes many genetic mutations in cancer cells, making them more visible to the immune system — and therefore more susceptible to a vaccine-driven immune response. Both Wu's original trial and the new Merck-Moderna results started there for that reason.

Melanoma has a very special place in cancer immunotherapies. It's a very unique disease that, to some level, is very immune-responsive, so it's a logical place to start. It's just like what Moderna and Merck have done: they've also started in melanoma. If it's not going to work in melanoma, then it's going to be challenged.— Dr. Catherine Wu, Dana-Farber Cancer Institute

The NIH initiative, Wu said, reflects how far the field has moved since her team's early proof-of-concept work — demonstrating that a vaccine could be built from a patient's individual DNA sequence, administered, and produce a measurable immune response.

The support from NIH has recognized the rapid progress made in this field and the potential to really deliver a new form of therapy that can render patients cancer-free.— Dr. Catherine Wu, Dana-Farber Cancer Institute

But Wu was direct about where the science still runs into walls. Vaccines work best when the burden of disease is low — after surgery, for instance, when most of the tumor has been removed and the immune system does not have to outpace rapid tumor growth. In kidney cancer trials conducted after surgery, Wu's team found that patients who received the vaccine showed no recurrence, whereas between 30 and 50 percent of similar patients typically see the disease return during that same window. Metastatic disease — cancer that has spread from its original site — is a much harder target.

The vaccine acts as a potent immune modulator, but if there's metastatic disease, that's a tough nut to crack. Vaccines can provide a lot of help, but they need other tools as well.— Dr. Catherine Wu, Dana-Farber Cancer Institute

Among the most difficult cancers to address are glioblastoma — the most common and aggressive brain cancer in adults — and ovarian cancer. Both cancers accumulate fewer genetic mutations than melanoma does, which lets them evade detection by the immune system. Wu's team is working on both, but she acknowledged they are unlikely to be among the first cancers where vaccines reach patients.

Those may not be the first ones out the gate because they're harder. We have to be inventive and creative about how we buttress the vaccine to address those challenges.— Dr. Catherine Wu, Dana-Farber Cancer Institute

The individualized nature of cancer vaccines — built from each patient's own tumor DNA — is both their greatest strength and a core manufacturing challenge. Wu pointed to it as the defining difference from conventional vaccines, and the reason a one-size-fits-all approach has not worked in oncology the way it has for infectious disease.

Cancer is a tougher nut to crack. With infections, it's typically a very limited repertoire of targets you're going after, so it's easier to focus the vaccine and to make it one-size-fits-all. In cancer, there's so much variation from individual to individual that a one-size-fits-all approach is challenging. It's the Achilles' heel of prior cancer therapies: that they weren't so individualized.— Dr. Catherine Wu, Dana-Farber Cancer Institute

Dana-Farber's Center for Cancer Vaccines continues research on personalized vaccines across melanoma, kidney cancer, glioblastoma, and other cancer types, according to the institute.

Why it matters — After a decade of foundational research, mRNA cancer vaccines are now showing statistically significant results in trials and attracting major federal funding — moving from proof-of-concept toward potential treatments for patients with melanoma and, eventually, harder-to-treat cancers.

⚠ Not yet confirmed

  • The Merck-Moderna melanoma vaccine was given post-surgery in combination with pembrolizumab.

Reported by bostonglobe.com, dana-farber.org

People in this story

Community

Be the first to comment.

Share this story
Text Email